Valion Bio Inc (VBIO) FinancialsVBIOValion Bio Inc

Evaluating the bottom line, Valion Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -476.11%, provide a clear picture of how effectively VBIO converts its operational activities into shareholder value.

In the context of the broader market, VBIO competes directly with industry leaders such as BRTX and XAIR. With a market capitalization of $2.06M, it holds a significant position in the sector. When comparing efficiency, VBIO's gross margin of N/A stands against BRTX's 68.13% and XAIR's 12.73%. Such benchmarking helps identify whether Valion Bio Inc is trading at a premium or discount relative to its financial performance.

The company has not generated revenue in multiple quarters, with total revenue of $146,000 in Q3 2025 being the only notable figure. The net income has been consistently negative, culminating in a loss of $6.4 million in Q1 2026, and a gross margin of -99.32% in Q3 2025.